Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1437-7772
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment ; volume:25 ; number:5 ; day:3 ; month:4 ; year:2020 ; pages:801-809 ; date:5.2020
International journal of clinical oncology ; 25, Heft 5 (3.4.2020), 801-809, 5.2020
- Urheber
-
Sato, Hiro
Okonogi, Noriyuki
Nakano, Takashi
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10147-020-01666-1
- URN
-
urn:nbn:de:101:1-2020071101241368312474
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sato, Hiro
- Okonogi, Noriyuki
- Nakano, Takashi
- SpringerLink (Online service)
Ähnliche Objekte (12)
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway